News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sartorius Stedim Biotech Recognized as Innovations Honoree for FlexMoSys



7/17/2012 12:34:21 PM

Goettingen, Germany, July 17, 2012 / B3C newswire / - Sartorius Stedim Biotech (SSB), a leading international pharma and biotech supplier, has been chosen as a 2012 Innovations Honoree for its unique new FlexMoSys production platform design by the American Pharmaceutical Manufacturing Magazine. Its jury members stated that this modular and mobile cleanroom system is improving quality and efficiency in pharmaceutical manufacturing significantly. The jury, which annually recognizes the best new products for pharmaceutical manufacturing, consists of the magazine's editorial team and a panel of bioprocessing experts.

The FlexMoSys module has been developed by G-Con Manufacturing and is equipped, distributed and installed by Sartorius Stedim Biotech. The system combines SSB's broad, single-use and reusable product portfolio and G-Con's novel cleanroom pods and thus offers a totally integrated production process platform. It enables GMP-compliant cleanroom space to be created that is faster, more flexible and significantly less expensive to set up and operate than a conventional, large purpose-built facility. Standard pods of the FlexMoSys cleanroom system come equipped with plumbing, data, video and voice interface, as well as provide many other features and benefits. In addition, the system can be conveniently tailored to a customer's specific needs as the customer can choose from an entire suite of fully integrated bioprocessing equipment like SSB's FlexAct solutions. The FlexMoSys pods can be easily moved due to installed air bearings underneath each pod. This is important when modular unit operations must be placed in a different sequence or a pod has to be decontaminated.

"FlexMoSys unlocks the full potential of customizable, cost-effective unit operations. It gives the biopharmaceutical industry a considerable head start in manufacturing biologics, such as vaccines," said Maik Jornitz, Senior Vice President of Marketing for Bioprocess Solutions at Sartorius Stedim Biotech. "Furthermore, it reflects the innovation potential of what we offer in cooperation with G-Con Manufacturing. The breakthrough revolution in biomanufacturing processes has now become a reality and has only just begun," he stated.

Image files:

FlexMoSys cleanroom pod:

http://www.sartorius.com/fileadmin/media/global/company/flexmosys_product.jpg

Maik Jornitz, Senior Vice President of Marketing for Bioprocess Solutions,Sartorius Stedim Biotech:

http://www.sartorius.com/fileadmin/media/global/company/maik_jornitz.jpg

Pharmaceutical Manufacturing Innovations 2012 Honoree - Logo:

http://www.sartorius.com/fileadmin/media/global/company/pr_201207_innovator_honoree_2012.jpg

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions."

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs more than 2,800 people, and in 2011 earned sales revenue of 477.3 million euros.

Contact:

Sartorius Stedim Biotech

Dominic Grone

Group Corporate Communications

+49.(0)551.308. 3324

dominic.grone@sartorius.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES